先聲藥業(02096.HK)治療認知障礙藥物獲藥監局批準臨牀試驗
先聲藥業(02096.HK)公佈,公司由Vivoryon Therapeutics N.V.區域授權的藥物SIM0408(鹽酸PQ912片),已獲得中國國家藥監局簽發的藥物臨牀試驗批準通知書,擬用於阿爾茨海默病(AD)導致的輕度認知障礙(MCI)或輕度癡呆的治療。
SIM0408是一種谷氨醯胺醯基環化(酉每)(QPCT)口服小分子抑制劑,正於歐洲開展IIb期臨牀研究。通過抑制QPCT從而防止毒性N3pE澱粉蛋白的形成,SIM0408可在疾病早期發揮作用,進而可能預防神經元的損傷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.